Applications published 22 April 2009

Gastro retentive delivery system
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2049078*

Compsns containing quaternary ammonium compound
sovagali Pharma 2049079*

A drug delivery system with thermoswitchable membranes
Koninklijke Philips Electronics 2049080*

Osmotic delivery systems and piston assemblies
Intarcia Therapeutics 2049081*

Reagents, methods and systems to suppress pro-inflammatory cytokines
Warsaw Orthopedic 2049082*

Stabilisation by preparing cyclodextrin inclusion complexes
Cargill 2049083*

Nanoparticulate sorafenib formulations
Elan Pharma International 2049084*

Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing the same
Flamel Technologies 2049085*

Process for manufacturing lactose
Glaxo Group 2049086*

Hydrophilic abuse deterrant delivery system
LAB International 2049087*

• Multi-particulate formulation having tramadol in immediate and controlled release form
The University of Kansas 2049088*

• Pharmaceutical tablets containing a plurality of active segments
Accu-Break Technologies 2049089*

• Use of h-HT7 receptor agonists for the treatment of pain
Laboratorios Del Dr Esteve 2049090*

• Casein complexes
DSM IP Assets 2049091*

• Compsns with enhanced elasticising activity
Polichem 2049092*

• Pharmaceutical compsn containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination
Sanofi-Aventis 2049093*

• Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
Cypress Bioscience 2049094*

• Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
Cypress Bioscience 2049095*

• Method of treating chronic myelogenous leukaemia cells
University of South Florida; Bristol-Myers Squibb 2049096*

• Compsn and method for binding acetaldehyde in stomach
Biohit 2049097*

• Omega-3 fatty acids for use in treating resistant hypertension
Reliant Pharmaceuticals 2049098*

• Compsns and methods for the treatment of mucositis
Resolvyx Pharmaceuticals 2049099*

• Therapeutic delivery of carbon monoxide
Hemocorm; University of Sheffield 2049100*

• Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
Cytovia 2049101*

• Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
Ranbaxy Laboratories 2049102*

• Inhibitors of undecaprenyl pyrophosphate synthase
Novartis; Novartis Pharma 2049103*

• Pyrrolidinone anilines as progesterone receptor modulators
SmithKline Beecham 2049104*

• Antimicrobial photodynamic therapy
CeramOptic 2049105*

• Pharmaceutical combination
Astex Therapeutics 2049106*

• Substituted imidazolone derivatives, preparation and uses
Genfit, Parc Eurasante 2049107*

• Treatment of endochrine dysfunction using iron chelators
Novartis 2049108*

• Combined use of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ARA-C) for the treatment of leukaemia
Sunesis Pharmaceuticals 2049109*

• Bridged diazepan orexin receptor antagonists
Merck & Co 2049110*

• Fungicidal azocyclic amides
EI du Pont de Nemours 2049111*

• Treating infections and sequelae thereof with combined dissociated glucocorticoid receptor agonists and anti-infective agents
Bausch & Lomb 2049112*

• Medicament for the enhancement of cognitive function and neuroprotection
Egis Gyogyszergyar 2049113*

• Hepatitis C virus inhibitors
Bristol-Myers Squibb 2049114*

• Alkyne-substituted pyridone compounds and methods of use
Amgen 2049115*

• Hepatitis C virus inhibitors
Bristol-Myers Squibb 2049116*

• Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
Auspex Pharmaceuticals 2049117*

• Morpholinyl and pyrrolidinyl analogues
SmithKline Beecham 2049118*

• Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1H-benzoimidazol-2-yl]-urea
Astex Therapeutics 2049119*

• Urotensin II receptor antagonists
Janssen Pharmaceutica 2049120*

• Methods and compsns for promoting activity of anti-cancer therapies
Oncology Research International 2049121*

• Methods and compsns for inhibiting angiogenesis
Oncology Research International 2049122*

• Delayed release glucocorticoid treatment of rheumatoid disease
Nitec Pharma 2049123*

• Phosphorus derivatives as histone deacetylase inhibitors
Merck 2049124*

• Treatment of cancer with 2-deoxygalactose
Landau, Bernard 2049125*

• Liposome treatment of viral infections
United Therapeutics Corp 2049126*

• N-methyanocarba derivatives to treat cardiac diseases
University of Connecticut 2049127*

• DUB3 as a cancer therapy target
The Queen's University of Belfast 2049128*

• Catecholamine receptor modulation
Yeda Research and Development 2049129*

• Soft tissue filler compsn comprising autologous dermis-derived cell culture product and hyaluronic acid
S-biomedics 2049130*

• Method of preparing plant extracts with a reduced content of unipolar environmental contaminants
Dr Wilmar Schwabe 2049131*

• Novel agents for the treatment of disorders connected to impaired neurotransmission
DSM IP 2049132*

• New eucalyptus extract, method of preparation and therapeutic uses thereof
Pierre Fabre Medicament 2049133*

• Compsns comprising rosehip and other active agents for the treatment of inflammatory disorders
DSM IP 2049134*

• Lactoferrin as a radioprotective agent
Agennix Inc 2049135*

• Mitochondria-targeted antioxidants
Natreon 2049136*

• Salicylanilides enhance oral delivery of therapeutic peptides
The Regents of the University of California 2049137*

• CLC channel ligand
Georgia Tech Research 2049138*

• Treatment of RAS-expressing tumours
Gloucester Pharmaceuticals 2049139*

• Kit and methods of an intervertebral disc
Kyphon SÀRL 2049140*

• Treatment for intimal hyperplasia and related conditions
Promics 2049141*

• Caspofungin formulations
Sandoz 2049142*

• Improved antibacterial antisense oligonucleotide and method
AVI BioPharma 2049143*

• Glycosylation of peptides via O-linked glycosylation sequences
Neose Technologies 2049144*

• PDGF-biomatrix compsns and methods for treating rotator cuff injuries
Biomimetic Therapeutics 2049145*

• Use of proteins of the SDF-1 family for improvement of axonal plasticity or for axonal regeneration following lesions
Mueller, Hans-Werner; Troescher, Herbert 2049146*

• Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
Apogenix 2049147*

• A stable liquid formulation of human growth hormone
Daewoong 2049148*

• Pegylated extended insulins
Novo Nordisk 2049149*

• Recombinant of transgenic factor VII compound having a majority of glycan, biantennary, bisalylated and non-fucosylated forms
LFB Biotechnologies 2049150*

• Methods and compsns for the treatment of cancer
Quintessence Biosciences 2049151*

• Antibodies for norovirus
Kim Laboratories 2049152*

• Attenuated polio viruses
National Biological Standards Board 2049153*

• Plasmids with immunological action
International Investment and Patents 2049154*

• Antitumour combinations containing taxane derivatives
Sanofi-Aventis 2049155*

• Compsns and methods for macular degeneration
The Cleveland Clinic Foundation 2049156*